Mark Lebwohl
Dermatology · New York, NYNPI 1013902444
Payments from drug & device makers
Across 1,526 payments — averaging $3771.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$1.1M
- AbbVie$894K
- Eli Lilly$818K
- Incyte Corporation$696K
- Janssen Research & Development, LLC$507K
- Boehringer Ingelheim$429K
- plus $1.3M from 45 others
Across 128 payments — averaging $1934.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$51K
- Amgen$48K
- UCB, Inc.$42K
- Eli Lilly$37K
- Pfizer$29K
- Bausch Health US, LLC$16K
- plus $24K from 7 others
What the payments were for
- Consulting fees$466,04264%
- Speaking & faculty fees$160,89822%
- Travel & lodging$51,4357%
- Food & beverage$26,1544%
- Education$28,1164%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,755,684 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SiliqBrodalumab | 21 | $107,208 |
| Dupixent PenDupilumab | 22 | $89,240 |
| Bexarotene | 12 | $63,042 |
| OtezlaApremilast | 11 | $58,268 |
| ZoryveRoflumilast | 11 | $9,691 |
| Acitretin | 23 | $6,273 |
| Mycophenolate Mofetil | 23 | $3,839 |
| Clobetasol Propionate | 75 | $3,758 |
| Tacrolimus | 21 | $2,148 |
| Mometasone Furoate | 93 | $1,582 |
| Doxycycline Hyclate | 18 | $946 |
| Fluticasone Propionate | 40 | $900 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 18 | $823 |
| Tretinoin | 16 | $766 |
| Mupirocin | 56 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq | $4,665 | $107,20821 claims |
| AmgenOtezla | $151,730 | $58,26811 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $412 | $9,69111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.
Other dermatology in New York
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Andrew AlexisNew York$5.7M
- Neil SadickNew York$4.2M
- Orit MarkowitzNew York$3.7M
- Alexandra GolantNew York$3.6M
- George HanNew York$3.4M
- David CohenNew York$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.